Stephanie Kauffman, Chief Executive Officer of the Melanoma Research Alliance, shared on LinkedIn:
“Yesterday’s FDA Advisory Committee vote recommending that the efficacy results from the IGNYTE trial are evaluable and clinically meaningful marks an important milestone for the melanoma community.
While the FDA‘s final decision is still pending, the discussion throughout the meeting reinforced something that has guided the Melanoma Research Alliance for nearly two decades:
‘Progress happens because of extraordinary patients who participate in clinical trials, researchers who refuse to give up, clinicians who push the science forward, and advocates who ensure the patient voice is heard.’
For people living with advanced melanoma whose disease has progressed despite existing therapies, every potential new treatment option matters.
At MRA, we believe that scientific rigor and patient urgency are not competing priorities. They are complementary ones. Patients deserve both strong evidence and relentless innovation.
Thank you to everyone who contributed to this important process – from the patients and families who shared their experiences, to the investigators, clinicians, advocates, FDA reviewers, and Advisory Committee members for their thoughtful consideration. I am also grateful for the leadership of MRA’s Chief Science Officer Joan Levy and MRA’s head of communications and patient engagement Dana Deighton for their testimony to this important panel, not only as leaders in melanoma research and patient engagement, but also through their personal experiences as cancer survivors themselves.
We now await the FDA‘s final decision in the days ahead.”
You can also read: ‘Third Time at the Table: Why Replimune’s RP1 Deserves a Real Hearing in Post-PD-1 Melanoma‘
